Pimozide

• Product Name Alternative:

  R6238

• UNSPSC Description:

  Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.

• Target Antigen:

  Adrenergic Receptor; Dopamine Receptor; Parasite; STAT

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;GPCR/G Protein;JAK/STAT Signaling;Neuronal Signaling;Stem Cell/Wnt

• Field of Research:

  Cancer; Neurological Disease; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/Pimozide.html

• Purity:

  99.91

• Solubility:

  DMSO : 16.67 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL

• Smiles:

  O=C1NC2=CC=CC=C2N1C3CCN(CCCC(C4=CC=C(F)C=C4)C5=CC=C(F)C=C5)CC3

• Molecular Weight:

  461.55

• References & Citations:

  [1]Ybema CE, et al. Adrenoceptors and dopamine receptors are not involved in the discriminative stimulus effect of the 5-HT1A receptor agonist flesinoxan. Eur J Pharmacol. 1994 Apr 21;256(2):141-7.|[2]Cai N, et al. The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. Am J Transl Res. 2017 Aug 15;9(8):3853-3866. eCollection 2017.|[3]Erik A. Nelson, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12): 3421-3429.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  2062-78-4